Markets
Tendies
@tendies
Bought NRX
Shares
0.0%
At 0.14, Exited 0.14
I believe NurExone is on the brink of significant growth after securing a master cell bank, positioning them to meet rising demand for their exosome-b...
Read
More
Thesis
I believe NurExone is on the brink of significant growth after securing a master cell bank, positioning them to meet rising demand for their exosome-based therapies. This acquisition paves the way for innovative treatments and partnerships, and I'm optimistic about their future revenues and market position.
Go back
Tendies
@tendies
Bought NRX
Shares
0.0%
At 0.14, Exited 0.14
I believe NurExone Biologic is on the brink of significant breakthroughs in regenerative medicine, especially after recent positive preclinical result...
Read
More
Thesis
I believe NurExone Biologic is on the brink of significant breakthroughs in regenerative medicine, especially after recent positive preclinical results. With the Orphan Drug Designation, the company has a strong upside potential as it capitalizes on its innovative therapies for CNS injuries.
Go back
Tendies
@tendies
Bought NRX
Shares
0.0%
At 0.14, Exited 0.14
I believe NurExone Biologic Inc. (NRX) is set for significant growth due to its promising ExoPTEN therapy for spinal cord injuries and efficient finan...
Read
More
Thesis
I believe NurExone Biologic Inc. (NRX) is set for significant growth due to its promising ExoPTEN therapy for spinal cord injuries and efficient financial management. With a lean share structure and strong market potential, this stock looks attractive for a swing trade. I've got my sights set on this one!
Go back
Tendies
@tendies
Bought NRX
Shares
0.0%
At 0.14, Exited 0.14
I'm really optimistic about NRX because of the massive potential in the spinal injury market and their innovative ExoPTEN nanodrug. With the increasin...
Read
More
Thesis
I'm really optimistic about NRX because of the massive potential in the spinal injury market and their innovative ExoPTEN nanodrug. With the increasing M&A activity and NRX's promising technology, I see a strong case for it becoming a takeover target, which could drive significant price appreciation.
Go back
Tendies
@tendies
Bought NRX
Shares
0.0%
At 0.14, Exited 0.14
Nurexone Biologics is on course for significant growth in regenerative medicine, with promising results from preclinical trials and expanding market p...
Read
More
Thesis
Nurexone Biologics is on course for significant growth in regenerative medicine, with promising results from preclinical trials and expanding market potential. The recent bullish Golden Cross signal suggests a positive trend change in the stock price.
Go back
